Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9

British Journal of Pharmacology

Volumn 163, Issue 5, 2011, Pages 1086-1098

  Berberich, Nina ^a   Uhl, Bernd ^b   Joore, Jos ^c   Schmerwitz, Ulrike K ^a   Mayer, Bettina A ^a   Reichel, Christoph A ^b   Krombach, Fritz ^b   Zahler, Stefan ^a   Vollmar, Angelika M ^a   Fürst, Robert ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Pepscan Presto BV   (Netherlands)

Author keywords

cyclin dependent kinases; endothelium; inflammation; leukocytes; roscovitine

Indexed keywords

CELL ADHESION MOLECULE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE; ROSCOVITINE; S6 KINASE; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

ANIMALS; APOPTOSIS; CELL ADHESION; CELL MOVEMENT; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASE 9; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GRANULOCYTES; HUMANS; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; PROTEIN KINASE INHIBITORS; PURINES;

EID: 79958818017     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01309.x     Document Type: Article

References (28)

1. Aldoss IT, Tashi T, Ganti AK, (2009). Seliciclib in malignancies. Expert Opin Investig Drugs 18: 1957-1965.
2. van Baal JW, Diks SH, Wanders RJ, Rygiel AM, Milano F, Joore J, et al,. (2006). Comparison of kinome profiles of Barrett's esophagus with normal squamous esophagus and normal gastric cardia. Cancer Res 66: 11605-11612. (Pubitemid 46094171)
3. Baez S, (1973). An open cremaster muscle preparation for the study of blood vessels by in vivo microscopy. Microvasc Res 5: 384-394.
4. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM, (2001). NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 8: 327-337. (Pubitemid 32831550)
5. Blagden S, de Bono J, (2005). Drugging cell cycle kinases in cancer therapy. Curr Drug Targets 6: 325-335. (Pubitemid 40667798)
6. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA, (2000). The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20: E83-E88.
7. Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP, (2008). R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 15: 263-273.
8. Du J, Wei N, Guan T, Xu H, An J, Pritchard KA, et al,. (2009). Inhibition of CDKS by roscovitine suppressed LPS-induced*NO production through inhibiting NFkappaB activation and BH4 biosynthesis in macrophages. Am J Physiol Cell Physiol 297: C742-C749.
9. Fu AK, Fu WY, Ng AK, Chien WW, Ng YP, Wang JH, et al,. (2004). Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity. Proc Natl Acad Sci U S A 101: 6728-6733. (Pubitemid 38586042)
10. Garriga J, Xie H, Obradovic Z, Grana X, (2010). Selective control of gene expression by CDK9 in human cells. J Cell Physiol 222: 200-208.
11. Hsieh WS, Soo R, Peh BK, Loh T, Dong D, Soh D, et al,. (2009). Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 15: 1435-1442.
12. Jhou RS, Sun KH, Sun GH, Wang HH, Chang CI, Huang HC, et al,. (2009). Inhibition of cyclin-dependent kinases by olomoucine and roscovitine reduces lipopolysaccharide-induced inflammatory responses via down-regulation of nuclear factor kappaB. Cell Prolif 42: 141-149.
13. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al,. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
14. Leitch AE, Haslett C, Rossi AG, (2009). Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. Br J Pharmacol 158: 1004-1016.
15. Leitch AE, Riley NA, Sheldrake TA, Festa M, Fox S, Duffin R, et al,. (2010). The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis. Eur J Immunol 40: 1127-1138.
16. Li L, Wang H, Kim J, Pihan G, Boussiotis V, (2009). The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD. Cell Cycle 8: 1794-1802.
17. Liu L, Schwartz B, Tsubota Y, Raines E, Kiyokawa H, Yonekawa K, et al,. (2008). Cyclin-dependent kinase inhibitors block leukocyte adhesion and migration. J Immunol 180: 1808-1817.
18. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, et al,. (2005). Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65: 5399-5407. (Pubitemid 40827353)
19. Maggiorella L, Aubel C, Haton C, Milliat F, Connault E, Opolon P, et al,. (2009). Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma. Cell Prolif 42: 38-48.
20. Mempel TR, Moser C, Hutter J, Kuebler WM, Krombach F, (2003). Visualization of leukocyte transendothelial and interstitial migration using reflected light oblique transillumination in intravital video microscopy. J Vasc Res 40: 435-441. (Pubitemid 37465091)
21. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C, (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279.
22. Nowak DE, Tian B, Jamaluddin M, Boldogh I, Vergara LA, Choudhary S, et al,. (2008). RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. Mol Cell Biol 28: 3623-3638. (Pubitemid 351732900)
23. Pfaffl MW, (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
24. Rosales JL, Lee KY, (2006). Extraneuronal roles of cyclin-dependent kinase 5. Bioessays 28: 1023-1034. (Pubitemid 44570451)
25. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, et al,. (2006). Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 12: 1056-1064. (Pubitemid 44353387)
26. Utreras E, Futatsugi A, Rudrabhatla P, Keller J, Iadarola MJ, Pant HC, et al,. (2009). Tumor necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35. J Biol Chem 284: 2275-2284.
27. Wang S, Fischer PM, (2008). Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 29: 302-313.
28. Zoja C, Casiraghi F, Conti S, Corna D, Rottoli D, Cavinato RA, et al,. (2007). Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. Arthritis Rheum 56: 1629-1637. (Pubitemid 46764092)